Objetivo The BLACANDI project aims to dramatically improve the diagnosis and management of bladder cancer patients by substituting a highly invasive and expensive test with a non-invasive and inexpensive test. Bladder cancer is the 6th most common cancer with an estimated 357,000 new cases worldwide every year, of which 180,000 are European. This type of cancer has the highest lifetime treatment costs per patient (pp) of all cancers. This high incidence, coupled with it’s relapsing nature, means that bladder cancer poses an enormous burden on health care systems. Current diagnostics and recurrence routine tests are performed through highly invasive and expensive procedures, such as cystoscopy. The Danish SME Genomic Expression Aps has licensed a technology composed of a patented filtration device that enhances the selection of tumor cells in urine, and aims at the clinical validation of a new combination of biomarkers.Our solution BLACANDI (Filtration Device in combination with selected biomarkers) is currently being tested in a small clinical trial in Denmark, in patients presenting with hematuria (blood in urine). Preliminary results indicate that the test can substitute cystoscopy identifying more than 90% of all bladder cancer patients.Substituting routine cystoscopy with the BLACANDI system could cut the cost of diagnosis and managing bladder cancer in half. In Europe the cost of diagnosing bladder cancer is €1.8 billion/year, thus we could save €900 million.Whereas the technology behind the filtration device and the selected biomarkers is already demonstrated, further maturation of the tests into fully commercial and operational solutions is hampered by the absence of a large clinical validation of the BLACANDI system. Furthermore, there is a need to corroborate our business strategy, since it requires customization to different health care systems. This phase 1 feasibility study provides us that opportunity. Ámbito científico medical and health sciencesclinical medicineoncologybladder cancermedical and health sciencesbasic medicinephysiologycytology Programa(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Tema(s) PHC-12-2014-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices Convocatoria de propuestas H2020-SMEInst-2014-2015 Consulte otros proyectos de esta convocatoria Convocatoria de subcontratación H2020-SMEINST-1-2014 Régimen de financiación SME-1 - SME instrument phase 1 Coordinador GENOMIC EXPRESSION APS Aportación neta de la UEn € 50 000,00 Dirección BORGSKRIVERVEJ 3 2 TH 2400 Kobenhavn Nv Dinamarca Ver en el mapa Pyme Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención. Sí Región Danmark Hovedstaden Byen København Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Enlaces Contactar con la organización Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 71 429,00
